The purpose of this research study is to determine the effectiveness of the "Teens Taking Charge IOP" on adolescents who have experienced trauma (and their caregivers).

The purpose of this study is to assess the efficacy and safety of a PPF-block to mitigate opioid use and improve headache pain control in patients with spontaneous SAH. The PPF block will be compared to placebo to determine if the block can effectively reduce headache symptoms and decrease subject's need for opioid treatment.

The ASPIRE trial aims to study anticoagulant medications in patients who have had an intracerebral hemorrhage (bleeding in the brain) who also have atrial fibrillation (irregular heartbeats). Participants who agree to study participation will receive either Aspirin or Apixaban and followed for 12-36 months to see if they have any other strokes, and follow their general recovery after stroke.

We are aiming to understand the current limits on diagnosing and treating neuroimmunological disorders in Africa from a clinician's point of view.

This study will explore how people living with mild dementia, their caregivers, and community members experience the respite for all model, a form of short-term caregiving. This study aims to understand how this model is acting as a form of social support.

The purpose of this study is to improve the technique of focused ultrasound surgery in treating essential tremors for adults whose tremors are not controlled by medication(s).

We are using specialized functional MRI for people receiving deep brain stimulation surgery to help predict who will benefit most from this procedure.

We want to understand the basis of the symptoms of psychosis in the brain and use imaging to predict them. The purpose of the study is to develop future treatments that target the particular symptoms that the patients present.

We intend to study sensations generated by spinal cord stimulation with the goal of using this knowledge to develop electrical interfaces that can restore loss of sensory function after neurological injury or disease.

This study compares two dose strengths of a new epilepsy medicine to placebo for treatment of refractory focal onset epilepsy as measured by the change in 28-day average seizure frequency.